Methyldopa Dosage in Pregnant Women with Hypertension

Initial Dosing Strategy

The European Society of Cardiology recommends starting with 750 mg daily in divided doses (typically 250 mg three times daily) for mild to moderate hypertension (BP 140-169/90-109 mmHg) 1
Maximum daily dose is 4 grams per day, divided into three or four doses, as recommended by the European Society of Cardiology 1

The European Society of Cardiology suggests beginning methyldopa when BP reaches ≥140/90 mmHg in women with gestational hypertension, pre-existing hypertension with superimposed gestational hypertension, or hypertension with subclinical organ damage 2, 3, 4
In other circumstances without these risk factors, treatment threshold is ≥150/95 mmHg, according to the European Society of Cardiology 2, 3, 4
Treatment should ideally begin before conception in women with known chronic hypertension, as recommended by the European Society of Cardiology 1

Target blood pressure is 140-150/90-100 mmHg to balance maternal protection while avoiding uteroplacental hypoperfusion, as suggested by clinical guidelines 5

Methyldopa remains the first-line agent for chronic hypertension in pregnancy due to its extensive safety record with no evidence of adverse effects on mothers or babies, including long-term pediatric follow-up, according to the European Society of Cardiology 1

Discontinue methyldopa postpartum due to the risk of postnatal depression; alternative agents should be used after delivery, as recommended by the European Society of Cardiology 2, 3, 4
Avoid overly aggressive blood pressure reduction (do not lower diastolic BP below 80 mmHg) as this can impair uteroplacental perfusion and compromise fetal development, according to clinical guidelines 5

For hypertensive emergencies (BP ≥170/110 mmHg), hospitalization is mandatory and oral methyldopa can be used alongside or instead of IV labetalol or oral nifedipine for immediate treatment, as suggested by the European Society of Cardiology 2, 3, 4

The European Heart Journal recommends discontinuing methyldopa immediately postpartum due to the risk of postnatal depression, and switching to alternative agents such as ACE inhibitors after delivery 6

The American Heart Association, as published in Circulation, suggests that while antihypertensive drugs should be avoided in the first trimester when possible, methyldopa is a notable exception with extensive first-trimester safety data, and beta-blockers, particularly atenolol, are associated with intrauterine growth retardation, especially with early gestational use 7